This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
March 27, 2018
Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
March 26, 2018
Strongbridge Biopharma plc to Host Investor and Analyst Day on April 5, 2018
March 22, 2018
Oncopeptides has completed a directed share issue of approximately SEK 314 million
March 21, 2018
BONESUPPORT™ – Positive clinical data for CERAMENT® G in infection management presented at BLRS 2018
March 20, 2018
Altimmune to Announce Year End 2017 Financial Results on March 29
March 20, 2018
Strongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
March 18, 2018
Strongbridge Biopharma plc Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
March 15, 2018
Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin® in Three Lymphoma Models at AACR 2018
March 15, 2018
Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting
March 15, 2018
Targovax ASA: Notice of Annual General Meeting